Board of Directors

Joseph F. Lovett (Chairman)

Mr. Lovett serves as Chairman of the Board of Esperance.  He is managing general partner at Louisiana Fund I and II and has more 36 years of experience in the life science field and has extensive experience managing venture capital funds. He received his Bachelor of Arts degree in economics from the University of Vermont and his Masters in Business Administration from California State Polytechnic University.

Ross P. Barrett

Mr. Barrett is the managing partner of BVM Capital, LLC, the management company for Louisiana Ventures, LP, the Themelios Funds and TransBio Ventures, LP. He is a co-founder of the software and data analytics company VC Experts, Inc. and is active in the management of the company. Previously, Mr. Barrett worked on Capitol Hill as a legislative aide to senior U.S. Senator, J. Bennett Johnston, where he specialized in appropriations, risk assessment and regulatory reform. He has been an adviser to or investor in over twenty early-stage privately held companies.  Mr. Barrett was appointed as Commissioner of the Louisiana Airport Authority from 2005-2008. In 2007, he was named to Governor Bobby Jindal’s Small Business and Entrepreneurship transition team.

Mr. Barrett currently is a member of Louisiana State Committee of 100 and is the current President of the Shreveport-Bossier Committee of 100.  He is a Trustee of Centenary College of Louisiana.  Ross holds a LLM. Degree in Taxation from the New York University School of Law, a J.D. from Louisiana State University School of Law, and a B.A. in Political Science from Southern Methodist University.

Hector W. Alila, D.V.M., Ph.D.

Dr. Alila is founding President and Chief Executive Officer of Experance.  He has more than 28 years of senior management experience in drug development in large pharmaceutical and biotech companies and research experience in academia. Prior to joining Esperance he served as Senior Vice President of Drug Development at Protalex, Inc. (New Hope, PA), Vice President of Product Development at Cell Pathways, Inc. in Horsham, PA, (later acquired by OSI Pharmaceuticals, which was acquired by Astellas Pharma Inc.), Director of Biology/Pharmacology at GeneMedicine, Inc. in The Woodlands, TX, (which merged with Megabios to become Valentis, Inc.) and several research, development, and management positions at SmithKline Beecham (now GlaxoSmithKline) in Pennsylvania. He obtained his veterinary degree from the University of Nairobi (Kenya) and continued his training at University of Pennsylvania to become a licensed veterinarian to practice in Pennsylvania and New York. He obtained his Ph.D. degree in physiology and immunology from Cornell University (Ithaca, NY) where he also held a faculty position as Senior Research Associate in Physiology at the Veterinary College. Dr. Alila has published over 40 scientific papers in peer-reviewed journals, 2 book chapters and holds 12 issued patents. Dr. Alila also serves on the board of several companies, state and philanthropic organizations. He is a recipient of several awards for his pioneering work in reproduction, anti-infective agents, autoimmune diseases and cancer.

Peter Hoang, MBA

Mr. Hoang is currently President & Chief Executive Officer and a member of the Board of Directors of TapImmune (Nasdaq: TPIV) a clinical-stage immuno-oncology company with ongoing clinical trials at the Mayo Clinic and Memorial Sloan-Kettering Cancer Center. Prior to TapImmune, he served as the Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals (Nasdaq: BLCM), a clinical stage immuno-oncology and cell therapy company developing small molecule-controllable gene-modified T cell-based therapeutics. Previously, Mr. Hoang led the new venture formation and development effort as the Managing Director, Innovations in the Strategic Industry Ventures department for The University of Texas MD Anderson Cancer Center.

In addition to his executive management experience leading publicly traded biotechnology companies, Mr. Hoang has over 18 years of capital markets and deal-making experience in investment banking and venture capital, advising on over 100 transactions with an aggregate deal value of over $120 billion. Prior to MD Anderson, Peter was a senior investment banker, most recently as Managing Director and head of global healthcare mergers & acquisitions advisory for CIT Group (NYSE: CIT). He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch and Deutsche Bank.  Mr. Hoang earned an M.B.A. with high honors distinction from the    Anderson School of Management at UCLA and a B.A. from Yale University.